[Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
Serotonin (5-HT) is a central neurotransmitter and a neuromodulator. This amine is involved in many physiological functions and pathological disorders. Most of its effects are mediated by specific 5-HT receptors. In the first part of this paper, the present knowledge of 5-HT receptors is reviewed in terms of both pharmacology and molecular biology. In the second part, the functional properties of 5-HT receptors are analyzed and their involvement in pathophysiological processes is discussed. Most 5-HT receptors belong to the G-protein-coupled receptor family (5-HT1, 5-HT2 and 5-HT4 receptors), whereas one is a member of the ligand-gated ion-channel receptor family (5-HT3 receptor). 5-HT1 receptors are characterized by their high affinity for 5-HT and comprise several subclasses. Most are negatively coupled to adenylate cyclase but the 5-HT1C subtype is linked to phospholipase C activation and resembles the 5-HT2 receptor. By contrast, the newly identified 5-HT4 receptor is positively coupled to adenylate cyclase. Most 5-HT receptors have now been cloned, but their physiological roles are not completely understood. Better knowledge of 5-HT receptors has already led to the development of new drugs, such as buspirone, a 5-HT1A partial agonist devoid of benzodiazepine-like properties for the treatment of generalized anxiety. Anxiolytic properties have also been reported for 5-HT2 and 5-HT3 receptor antagonists. A new and potent anti-migrainous drug, sumatriptan, has recently been selected among compounds obtained by research on the 5-HT1D receptor. This key receptor controls the release of monoamines, amino acids and peptides, and new drugs are expected in the near future. The therapeutic potential of 5-HT3 antagonists is impressive, as these compounds have potent antiemetic, promnesic and antipsychotic properties in various animal models. Two such drugs have already been marketed for the prevention of radiation-induced emesis (ondansetron and granisetron) and are more potent than the antidopaminergic drugs. Many other data suggest that 5-HT receptors might be involved in other illnesses. Some drugs are in the development phase but identification of the relevant receptor is often difficult. Furthermore, the lak of specific ligands for some receptors clearly hinders functional correlations.
Moulignier
A
A
Service de Neurologie, Hôpital Tenon, Paris.
D001008:Anxiety Disorders / Q000188:drug therapy / Q000503:physiopathology; D002490:Central Nervous System / Q000737:chemistry* / Q000502:physiology; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000503:physiopathology; D003866:Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology; D011618:Psychotic Disorders / Q000188:drug therapy / Q000503:physiopathology; D011985:Receptors, Serotonin / Q000032:analysis / Q000502:physiology; D012701:Serotonin / Q000378:metabolism / Q000502:physiology; D012702:Serotonin Antagonists / Q000627:therapeutic use
D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin
Récepteurs centraux de la sérotonine. Principaux aspects fondamentaux et fonctionnels. Applications thérapeutiques.